Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
PROCEDURE

Hepato-celiac lymphadenectomy

Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).

Trial Locations (1)

Unknown

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
collaborator

Fudan University

OTHER

lead

Shanghai Gynecologic Oncology Group

OTHER_GOV